Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced today that the Company’s management team will participate in Biotech Showcase and present at the 19th Annual Non-Dilutive Funding Summit. Both events will be held in-person and are scheduled alongside the J.P. Morgan 42nd Annual Healthcare Conference 2024.
Related news for (MRKR)
- Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
- 24/7 Market News Snapshot 06 October, 2025 – Marker Therapeutics, Inc. Common Stock (NASDAQ:MRKR)
- Morning Market Surge: Biotech Bulls Lead Charge with FDA Wins and Breakthrough Trial Data
- Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
- Marker Therapeutics Reports Promising Phase 1 Lymphoma Trial of MT-601 Responses
